MxA protein - An interferon beta biomarker in primary progressive multiple sclerosis patients

European Journal of Neurology

Volumn 15, Issue 8, 2008, Pages 822-826

  Millonig, A ^a   Dressel, A ^b   Bahner, D ^b   Bitsch, A ^b   Bogumil, T ^b   Elitok, E ^b   Kitze, B ^b   Tumani, H ^b   Weber, F ^b   Gneiss, C ^a   Deisenhammer, F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Biomarker; Clinical trial; Interferon beta; Multiple sclerosis; MxA; Neutralizing antibodies; Primary progressive multiple sclerosis

Indexed keywords

INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; BETA INTERFERON; BIOLOGICAL MARKER; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA-1B; MYXOVIRUS RESISTANCE PROTEINS;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG ACTIVITY; DRUG SAFETY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT RESPONSE; ADOLESCENT; AREA UNDER THE CURVE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE;

EID: 54549124515     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02190.x     Document Type: Article

References (32)

1. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005; 65: 1919-1923.
2. Ebers GC. Natural history of primary progressive multiple sclerosis. Multiple Sclerosis 2004; 10(Suppl. 1): S8-S13.
3. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs 2005; 19: 369-376.
4. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44-51.
5. Montalban X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Multiple Sclerosis 2004; 10(Suppl. 1): S62-S64.
6. Gilli F, Bertolotto A, Sala A, et al. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagon-ization of IFN-beta-mediated suppression of MMPs. Brain 2004; 127: 259-268.
7. Gilli F, Marnetto F, Caldano M, et al. Biological markers of interferon-beta therapy: comparison among interferon- timulated genes MxA, TRAIL and XAF-1. Multiple Sclerosis 2006; 12: 47-57.
8. Wandinger KP, Lunemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. The Lancet 2003; 361: 2036-2043.
9. Santos R, Weinstock-Guttman B, Tamano-Blanco M, et al. Dynamics of interferon-beta-modulated mRNA bi-omarkers in multiple sclerosis patients with anti-inter-eron-beta neutralizing antibodies. Journal of Neuroimmunology 2006; 176: 125-133.
10. Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IF-Nbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003; 61: S24-S26.
11. Deisenhammer F, Reindl M, Harvey J, et al. Bioavail-ability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239-1243.
12. Deisenhammer F, Mayringer I, Harvey J, et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 2000; 54: 2055-2060.
13. Bertolotto A, Gilli F, Sala A, et al. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative competitive PCR method for MxA quantification. Journal of Immunological Methods 2001; 256: 141-152.
14. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003; 60: 634-639.
15. von Wussow P, Jakschies D, Hochkeppel HK, et al. The human intracellular Mx homologous protein is specifically induced by type I interferons. European Journal of Immunology 1990; 20: 2015-2019.
16. Kracke A, von Wussow P, Al Masri AN, et al. Mx proteins in blood leukocytes for monitoring interferon beta- 1b therapy in patients with MS. Neurology 2000; 54: 193-199.
17. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with ultiple sclerosis. Neurology 2008; 70: 1119-1127.
18. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Annals ofNeurology 2000; 47: 831-835.
19. Yushchenko M, Mader M, Elitok E, et al. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. Journal of Neurology 2003; 250: 1224-1228.
20. Bitsch A, Dressel A, Meier K, et al. Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. Journal of Neurology 2004; 251: 1498-1501.
21. Bitsch A, Bahner D, Wachter C, et al. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis. Acta Neurologica Scandinavica 2004; 110: 386-392.
22. Dressel A, Kolb AK, Elitok E, et al. Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis. Acta Neurologica Scandi-navica 2006; 114: 368-373.
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
24. Kurtzke JF. A proposal for a uniform minimal record of disability in multiple sclerosis. Acta Neurologica Scandi-navica 1981; 64: 110-129.
25. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1996; 47: 889-894.
26. Vartanian TK, Zamvil SS, Fox E, Sorensen PS. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 2004; 63: S42-S49.
27. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266-1272.
28. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. The Lancet 2003; 362: 1184-1191.
29. Vartanian T, Solberg SP, Rice G. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. Journal ofNeurology 2004; 251(Suppl. 2): II25-II30.
30. Oliver B, Mayorga C, Fernandez V, et al. Interferon receptor expression in multiple sclerosis patients. Journal of Neuroimmunology 2007; 183: 225-231.
31. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
32. Montalban X. Primary progressive multiple sclerosis. Current Opinion in Neurology 2005; 18: 261-266.